You Are Invited to a LIVE CME/CPE/CNE Webcast Event
To register, please click the link at the bottom of this page.
Control Versus Cure? How to Determine the Value of Oncology Treatments Within Managed Care: A Focus on Multiple Myeloma Live Webcast Dates DAY DATE TIME Wednesday June 4, 2014 12:00 PM - 1:30 PM EDT Hot Topics Include: Point/counter-point debate on value proposition of multiple myeloma drug sequences, treatment combinations, and duration of therapy Response criteria to select and assess treatment success/outcomes Innovative oncology pharmacy benefit models and specialty pharmacy management services Decision-support tools, including comparative effectiveness research (CER), to improve therapeutic decision-making Effective supportive care strategies in oncology Best practices in collaborating with the comprehensive care team to reduce treatment variability Target Audience Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs) Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with multiple myeloma including: physicians, pharmacists, registered nurses, and case managers Program Overview Leaders from managed care organizations (MCOs) and other payers have identified the management of multiple myeloma (MM) as a priority area for optimizing clinically- and economically-appropriate care for their members. In light of new drug developments as well as expanding uses of current agents, payers need to appropriately and effectively design benefits that optimize both cost-efficiency and patient outcomes. The webcast will include a unique point/counter-point design to debate the value proposition of MM drug sequences, treatment combinations, and duration of therapy. The faculty panel includes an academic hematologist, a community-based hematologist, and managed care experts. Educational Objectives After completing this activity, the participant should be better able to: Discuss the nature and validity of current debates among members of the hematology community regarding therapeutic decision-making for MM patients, including the clinical data that support various perspectives Demonstrate the value of comparative effectiveness research (CER) as a decision-support tool to appropriately invest resources and reduce treatment variability among MM patients Implement innovative oncology pharmacy benefit models and specialty pharmacy management services Provide accurate and appropriate counsel as part of the managed care treatment team Provide appropriate care and counsel for patients and their families.
Distinguished Faculty Presenters Rafat Abonour, MD Professor of Medicine Medical Director, Bone Marrow Transplant Program Medical Director, Stem Cell Laboratory Indiana University Simon Cancer Center Diana Brixner, PhD, RPh Professor and Chair, Department of Pharmacology Executive Director Outcomes Research Center, College of Pharmacy Director of Outcomes, Personalized Health Care Program University of Utah Jeffrey D. Dunn, PharmD, MBA Senior Vice President VRx Pharmacy Services, LLC James Kenney, Jr., RPh, MBA Pharmacy Operations Manager Harvard Pilgrim Health Care, Inc. Joseph Mikhael MD, MEd, FRCPC, FACP Associate Dean, Mayo School of Graduate Medical Education Deputy Director - Education, Mayo Clinic Cancer Center Associate Professor, Mayo College of Medicine Mayo Clinic in Arizona
Agenda     Pre-Activity Assessment and Evaluation     Opening Comments     Jeffrey D. Dunn, PharmD, MBA     A Brief Introduction to Multiple Myeloma     Joseph Mikhael MD, MEd, FRCPC, FACP     Debates in Multiple Myeloma Management: Diagnosis and Risk Stratification     Rafat Abonour, MD     Treatment Selection and Duration of Therapy     Joseph Mikhael MD, MEd, FRCPC, FACP     Applying CER as a Decision-Support Tool for Anti-Myeloma Agents to Reduce Treatment Variability     Diana Brixner, PhD, RPh     James Kenney, Kenney, Jr., RPh, MBA     Collaborating to Improve Care of Multiple Myeloma Patients:     Pharmacy Benefit Designs and Specialty Pharmacy Cancer Care Services     Jeffrey D. Dunn, PharmD, MBA     Audience Q&A Session     Key Takeaways and Closing Comments     Post-Activity Assessment and Evaluation Accreditation Statements Physician Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Pharmacist Accreditation Statement Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Credit Designation Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-14-092-L01-P) Upon receipt of the completed activity evaluation form, transcript information will be available at www .mycpemonitor.net within 4 weeks. Type of Activity: Application Nursing Credit Designation This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine. Nursing Accreditation Statements Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. A statement of credit will be issued only upon receipt of a completed activity evaluation form.
Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity. Hardware/Software Requirements Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.x, and Google Chrome 10 and up. Fee Information There is no fee for this educational activity. If you have any questions, please call (215) 619-8812 or email info@impactedu.net.
Please click here to register.